Dallas, TX -- (SBWIRE) -- 09/19/2014 -- New PharmaPoint Drug Evaluation report, "Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Complete Report Details
http://www.reportsnreports.com/reports/298120-cinquil-reslizumab-asthma-forecast-and-market-analysis-to-2023.html

Cinquil is a humanized mAb targeting IL-5, a cytokine that regulates the activation of eosinophils. Teva added Cinquil to its portfolio as part of the Cephalon acquisition in 2011. Cinquil is currently being studied in both eosinophilic esophagitis and asthma. The importance of eosinophilic airway inflammation, which is present in 40- 60% of the severe asthmatic population, is evidenced by the number of companies targeting this patient segment. Of all the products in the pipeline that lead to eosinophil depletion, the most advanced ones target the IL-5 pathway.

Scope:

-Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

-Detailed information on Cinquil including product description, safety and efficacy profiles as well as a SWOT analysis.

-Sales forecast for Cinquil for the top eight countries from 2013 to 2023.

-Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Order a Purchase copy
http://www.reportsnreports.com/Purchase.aspx?name=298120

Reasons to Buy:

-Understand and capitalize by identifying products that are most likely to ensure a robust return

-Stay ahead of the competition by understanding the changing competitive landscape for Asthma

-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

-Make more informed business decisions from insightful and in-depth analysis of Cinquil performance

-Obtain sales forecast for Cinquil from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports

3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms

4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs

4.1.3 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment

6 Unmet Need and Opportunity
6.1 Overview
6.2 Personalized Therapies to Control Severe Asthma
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Better Patient Compliance
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Lower Cost of Asthma Medications
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Proper Diagnosis of Asthma in Children
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity

7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development

8 Cinquil (reslizumab)
8.1 Overview
8.2 Efficacy
8.3 Safety
8.4 Dosing and Formulation
8.5 Potential Clinical Positioning
8.6 Potential Commercial Positioning
8.7 Pricing and Reimbursement
8.8 SWOT Analysis
8.9 Forecast

9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Asthma Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 General Pricing Assumptions
9.4.4 Generic Erosion
9.4.5 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in This Study
9.6 About the Authors
9.6.1 Author
9.6.2 Author/Reviewer
9.6.3 Reviewer
9.6.4 Global Head of Healthcare
9.7 About GlobalData
9.8 Contact Us
9.9 Disclaimer

List of Tables
Table 1: Symptoms of Asthma
Table 2: Treatment Guidelines for Asthma by Country
Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
Table 6: Leading Treatments for Asthma, 2014
Table 7: Unmet Need and Opportunity in Asthma
Table 8: Asthma - Late Stage Pipeline, 2014
Table 9: Product Profile - Cinquil
Table 10: Efficacy of Cinquil Versus Placebo
Table 11: Cinquil's Safety Profile
Table 12: Cinquil SWOT Analysis, 2014
Table 13: Global Sales Forecast ($) for Cinquil, 2013-2023
Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Stepwise Disease Management Approach for Asthma in Adults
Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Asthma, 2013-2023

Browse more reports on Pharmaceuticals Market
http://www.reportsnreports.com/market-research/pharmaceuticals/